Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 12/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359303 | 1.00 | SERPINE1 (1.00) | SERPINE1CYP1A2CYP2C9CYP2C19RAF1 | |
| SCHEMBL7355877 | 0.91 | SERPINE1 (0.84) | SERPINE1CYP1A2CYP2C9CYP2C19RAF1 | |
| SCHEMBL7355888 | 0.91 | SERPINE1 (0.84) | SERPINE1CYP1A2CYP2C9CYP2C19RAF1 | |
| SCHEMBL7358028 | 0.90 | SERPINE1 (1.00) | SERPINE1 | |
| SCHEMBL7358033 | 0.90 | SERPINE1 (1.00) | SERPINE1 | |
| SCHEMBL7353995 | 0.89 | SERPINE1 (1.00) | SERPINE1HTR7 | |
| SCHEMBL7363197 | 0.89 | SERPINE1 (0.82) | SERPINE1 | |
| SCHEMBL7363192 | 0.89 | SERPINE1 (0.82) | SERPINE1 | |
| SCHEMBL7357832 | 0.89 | SERPINE1 (0.80) | SERPINE1HTR7KAT2BHTR1A | |
| SCHEMBL7357820 | 0.89 | SERPINE1 (0.80) | SERPINE1HTR7KAT2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | THE UNIVERSITY OF CHICAGO (US) | 2025-08-12 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240382452-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023086343-A1 | COMPOSITIONS AND DOSAGE FORMS FOR TOPICAL AND TRANSDERMAL DELIVERY OF ACTIVES AND METHODS OF USE | OPHIREX, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| US-5945297-A | Process for screening candidate agents that modulate the hemostatic system | METAXEN LLC (US) | 1999-08-31 | — | — | US | disclosed |
| US-5750530-A | PLASMINOGEN ACTIVATOR INHIBITORS | XENOVA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| WO-1995032190-A2 | PHARMACEUTICAL DIKETOPIPERAZINE COMPOUNDS | XENOVA LIMITED (GB) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | SERPINE1 53/4885CYP1A2 2739/4885CYP2C9 3946/4885 |
| US-12383579-B2 | Materials and methods of using an inhibitor of plasminogen activation to treat anastomotic leak | PLAT, PLG, SERPINB10 | SERPINE1 4/4885CYP1A2 4607/4885CYP2C9 4214/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | SERPINE1 4460/4885CYP1A2 1810/4885CYP2C9 957/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | SERPINE1 4685/4885CYP1A2 852/4885CYP2C9 27/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | SERPINE1 4685/4885CYP1A2 852/4885CYP2C9 27/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | SERPINE1 4568/4885CYP1A2 1072/4885CYP2C9 35/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | SERPINE1 4568/4885CYP1A2 1072/4885CYP2C9 35/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | SERPINE1 4835/4885CYP1A2 1539/4885CYP2C9 723/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | SERPINE1 4394/4885CYP1A2 1668/4885CYP2C9 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.